Developing a New Generation of TNFα Antagonists for the Treatment of Rheumatoid Arthritis

Table 1.

Anti-TNFα Biotherapeutics Currently Licensed for the Treatment of RA

	infliximab (Remicade^® )	adalimumab (Humira™)	etanercept (Enbrel^® )
Structure	Chimeric monoclonal Antibody	Recombinant human monoclonal antibody	p75 TNF receptor/ Fc fusion protein
Specificity	Soluble (trimer andmonomer) TNFα , transmembrane TNFα receptor-bound TNFα	Soluble TNFα and transmembrane TNFα , and	Soluble and transmembrane TNFα and lymphotoxin
Cell lysis	Yes	Yes	No
Maintenance dosing	3 mg/kg every 8 weeks via intravenous infusion	40 mg every 2 weeks subcutaneously	25 mg twice weekly subcutaneously
Serum half-life	8–10 days	14–19 days	4.8 days
Immune 8.5% response inRA patients		5%	5%